Cancer Archives

News and Trends 7 Jan 2020

Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug

Update (07/01/2020): Shanghai Miracogen has expanded its pre-existing license agreement with the Dutch biotech Synaffix. Under the terms of the new agreement, the Chinese pharma will use Synaffix’s antibody-drug conjugate technology to develop a second drug for the treatment of cancer. No financial details were disclosed. Published 10/04/2019: Shanghai Miracogen will pay up to €111M […]

January 7, 2020 - 2 minutesmins - By Jonathan Smith

Interview 18 Dec 2019

How BioNTech Navigates the Biotech Fundraising Maze

BioNTech is on a mission to individualize cancer therapy by developing a range of different innovative therapies, a task that can be a rollercoaster ride, according to its Chief Business and Commercial Officer Sean Marett. It’s been an interesting year for the German biotech. In July the company raised one of the biggest ever European […]

December 18, 2019 - 6 minutesmins - By Helen Albert

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 18 Dec 2019

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

Basel-based Cellestia Biotech has closed a €18M Series B financing round to help progress its first-in-class, targeted cancer drug to the clinic. The Swiss company is focusing on treating cancers that have a mutation in the Notch pathway, a group of proteins that helps cells communicate with each other. Many cancers have mutations in these […]

December 18, 2019 - 2 minutesmins - By Helen Albert

cancer immunotherapy immunos therapeutics

News and Trends 11 Dec 2019

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […]

December 11, 2019 - 2 minutesmins - By Jonathan Smith

Interview 11 Dec 2019

Collaboration Between Founders and Investors Primes Biotech Startups for Success

How can entrepreneurs work with investors to maximize the chances of their company succeeding? Venture capital partner Nanna Lüneborg and biotech entrepreneur Mai-Britt Zocca spoke at Labiotech Refresh in Copenhagen about their experiences in founding IO Biotech, a Danish biotech startup that develops cancer immunotherapies. Zocca and Lüneborg were both involved in setting up IO […]

December 11, 2019 - 5 minutesmins - By Jonathan Smith

News and Trends 9 Dec 2019

Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy

London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. Since their arrival on the market in 2017, CAR T-cell therapies have provided hope to patients with rare forms of blood […]

December 9, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

colorectal cancer mologen cancer immunotherapy

News and Trends 6 Dec 2019

Update: Cancer Immunotherapy Biotech Files for Insolvency

Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […]

December 6, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Dec 2019

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […]

December 4, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 21 Nov 2019

€37.4M Invested in Azeria Therapeutics’ Cancer Treatment Program

UK-based Azeria Therapeutics has raised a Series B investment round of €37.4M to fund development of novel breast cancer drugs targeting proteins called pioneer factors. The series B financing includes a €34.5M commitment from leading UK healthcare VC firm Syncona. The remainder was provided by the CRT Pioneer Fund — a specialist UK fund dedicated […]

November 21, 2019 - 3 minutesmins - By External Contributor

News and Trends 19 Nov 2019

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

The French company CarThera has teamed up with the US firm Kiyatec to study the effects on individual patients of an ultrasound therapy to deliver brain cancer drugs to the brain. Under the agreement, Kiyatec will test the effects of chemotherapy on cells taken from CarThera’s ongoing phase I/II trial in patients with brain cancer. […]

November 19, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Nov 2019

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors. The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy […]

November 12, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 11 Nov 2019

Argenx Raises Whopping €502M in Global Offering

The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels. Argenx’s global offering was launched last week. It consists of a private placement in Europe as well as a public offering in the […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug

How BioNTech Navigates the Biotech Fundraising Maze

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

Collaboration Between Founders and Investors Primes Biotech Startups for Success

Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy

Update: Cancer Immunotherapy Biotech Files for Insolvency

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

€37.4M Invested in Azeria Therapeutics’ Cancer Treatment Program

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

Argenx Raises Whopping €502M in Global Offering

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!